Zang Wei-Jin, Sun Lei, Yu Xiao-Jiang
Division of Cardiovascular Physiology and Pharmacology, Department of Pharmacology, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China.
Sheng Li Xue Bao. 2007 Oct 25;59(5):593-600.
The recent discovery of ischemic postconditioning is a landmark of anti-reperfusion injury. The medical community has a preference for postconditioning because it is easier to control in clinic and has reliable benefits to heart compared with preconditioning. Postconditioning is defined as a series of brief mechanical interruptions of blood flow applied at the very onset of reperfusion. It can reduce irreversible post-ischemic injury and protect myocardium. There are two important factors in the algorithm of postconditioning: cycle number and duration of intermittent episodes. The latter may depend on species and is more important than cycle number. Postconditioning-induced infarct-sparing effect persists not only after the acute phase of reperfusion but also after a prolonged reperfusion. However, whether cardioprotection of postconditioning is related to preservation of endothelial function and attenuation of oxidative damage is still under debate. Up-regulating the reperfusion injury salvage kinase (RISK) pathway is one of the most important mechanisms in cardioprotection of postconditioning, including activation of phosphatidylinositol 3-kinase (PI3K)-Akt and/or extracellular signal-regulated kinase (ERK), which reduces apoptosis and necrosis by inhibiting the opening of mitochondrial permeability transition pore (mPTP). But the signal transduction of these two pathways needs further research. In order to be more suitable for clinical application, researchers translate mechanical maneuver into drug intervention to investigate whether drug can simulate ischemic postconditioning in cardioprotection, termed pharmacological postconditioning. Adenosine is one of the most extensive and prospective drugs in pharmacological postconditioning study. However, in our laboratory we demonstrate that acetylcholine is able to induce pharmacological postconditoning through mitochondrial ATP-sensitive potassium channel. The present article reviews the protective effects and signal transduction of postconditioning, especially the mechanisms and clinical application of adenosine- and acetylcholine-induced pharmacological postconditioning.
缺血后适应的近期发现是抗再灌注损伤领域的一个里程碑。医学界更倾向于后适应,因为它在临床上更容易控制,而且与预处理相比,对心脏具有可靠的益处。后适应被定义为在再灌注开始时施加的一系列短暂的血流机械性中断。它可以减少不可逆的缺血后损伤并保护心肌。后适应的算法中有两个重要因素:循环次数和间歇性发作的持续时间。后者可能因物种而异,并且比循环次数更重要。后适应诱导的梗死面积缩小效应不仅在再灌注急性期后持续存在,而且在长时间再灌注后也持续存在。然而,后适应的心脏保护作用是否与内皮功能的保留和氧化损伤的减轻有关仍存在争议。上调再灌注损伤挽救激酶(RISK)途径是后适应心脏保护中最重要的机制之一,包括磷脂酰肌醇3激酶(PI3K)-Akt和/或细胞外信号调节激酶(ERK)的激活,通过抑制线粒体通透性转换孔(mPTP)的开放来减少细胞凋亡和坏死。但这两条途径的信号转导还需要进一步研究。为了更适合临床应用,研究人员将机械操作转化为药物干预,以研究药物是否能模拟缺血后适应的心脏保护作用,即药物后适应。腺苷是药物后适应研究中应用最广泛且最具前景的药物之一。然而,在我们实验室,我们证明乙酰胆碱能够通过线粒体ATP敏感性钾通道诱导药物后适应。本文综述了后适应的保护作用和信号转导,特别是腺苷和乙酰胆碱诱导的药物后适应的机制及临床应用。